A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 25 (11) , 759-779
- https://doi.org/10.2165/00002018-200225110-00002
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- Comparison of Bimanual Examination With Ultrasound Examination Before Hysterectomy for Uterine LeiomyomaPublished by Wolters Kluwer Health ,1998
- Interferon‐α is a Potent Inhibitor of Basic Fibroblast Growth Factor‐Stimulated Cell Proliferation in Human Uterine CellsAmerican Journal of Reproductive Immunology, 1998
- GoserelinDrugs, 1996
- Steroidal Treatment of Myomas: Preoperative and Long-Term Medical TherapySeminars in Reproductive Medicine, 1992
- GoserelinDrugs, 1991
- How maximal is "maximum"?The Lancet, 1990
- Uterine fibroids: A clinical reviewBJOG: An International Journal of Obstetrics and Gynaecology, 1990
- Termination of Early Pregnancy by the Progesterone Antagonist RU 486 (Mifepristone)New England Journal of Medicine, 1986
- Aromatase activity in uterine leiomyomataJournal of Steroid Biochemistry, 1984
- Purification, amino acid composition and N-terminus of the hypothalamic luteinizing hormone releasing factor (LRF) of ovine originBiochemical and Biophysical Research Communications, 1971